EGFR + NSCLC Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment
Explore our latest breakthroughs in EGFR + NSCLC research. Learn more about our innovative pipeline today! @ EGFR + NSCLC Pipeline Outlook
Key Takeaways from the EGFR + NSCLC Pipeline Report
In July 2025, ETOP IBCSG Partners Foundation announced a primary objective of the trial is to assess the efficacy of amivantamab and bevacizumab added to continued treatment with the third-generation EGFR-TKI lazertinib, in patients with EGFR-mutant advanced NSCLC, who have been previously treated with a third-generation EGFR-TKI in order to provide data on treatment effect and sample size required for a future phase III trial.
In June 2025, BlossomHill Therapeutics conducted a study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and/or human epidermal growth factor receptor (HER2) mutations. The study drug, BH-30643 capsules, will be self-administered by mouth twice daily in 21-day cycles.
In June 2025, Merck Sharp & Dohme LLC organized a study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs).
DelveInsight's EGFR + NSCLC pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for EGFR + NSCLC treatment.
The leading EGFR + NSCLC Companies such as Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux Therapeutics, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Genor Biopharma, J Ints Bio, Avistone Pharmaceuticals, Mythic Therapeutics and others.
Promising EGFR+NSCLC Pipeline Therapies such as IN10018, Furmonertinib, Oral S-1 + Oral Osimertinib, YH25448, JS111 capsules (AP-L1898), Osimertinib, Gefitinib, RC108, Sunvozertinib, and others.
Stay informed about the cutting-edge advancements in EGFR + NSCLC treatments. Download for updates and be a part of the revolution in cancer care @ EGFR + NSCLC Clinical Trials Assessment
EGFR + NSCLC Emerging Drugs Profile
CLN-081 is a novel irreversible Epidermal Growth Factor Receptor (EFGR) inhibitor. It is administered through oral route, and is developed by Cullinan Oncology. The drug is being developed in association with Taiho Pharmaceuticals. The drug is currently being investigated in the Phase III stage of development for the treatment of EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC).
BPI-361175: Betta Pharmaceuticals
BPI-361175 is a novel, oral, highly potent and selective 4th generation EGFR inhibitor developed by Betta Pharmaceutical Co., Ltd. The new chemical entity targets EGFR C797S mutation and other EGFR related mutations that are resistant to 3rd generation EGFR TKI in non-small cell lung cancer (NSCLC) and other solid tumors. It shows excellent inhibitory effect and selectivity in vitro assay and exhibits significant anti-tumor activity in a variety of xenograft models harboring EGFR C797S or other related mutations. The IND application of BPI-361175 has been approved by NMPA. Currently, the drug is the Phase I/II stage of its development for the treatment of Non-small Cell Lung Cancer.
G1T38: G1 Therapeutics
G1T38 is an investigational, oral CDK4/6 inhibitor designed to be used along with other targeted therapies for various oncology indications. G1 Therapeutics has entered a clinical trial collaboration to assess its G1T38 in combination with AstraZeneca's Tagrisso (osimertinib) in a Phase Ib/II clinical trial to treat patients suffering from EGFR mutation-positive non-small cell lung cancer (NSCLC). Currently, the drug is being evaluated in the Phase I/II stage in combination with osimertinib in patients with EGFR mutation-positive metastatic non-small cell lung cancer.
JANX008: Janux Therapeutics
JANX008, is a TRACTr that targets Epidermal Growth Factor Receptor (EGFR), and is being developed by Janux Therapeutics for the treatment of various solid tumors including non-small cell lung cancer. According to preclinical studies, JANX008 showed potent cleavage dependent anti-tumor activity, with limited toxicities in healthy tissues or CRS. JANX008, is currently being evaluated in phase I clinical trial for the treatment of various solid tumors.
The EGFR + NSCLC Pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of EGFR + NSCLC with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for EGFR + NSCLC Treatment.
EGFR + NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
EGFR + NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the EGFR + NSCLC market.
Learn more about EGFR + NSCLC Drugs opportunities in our groundbreaking EGFR + NSCLC research and development projects @ EGFR + NSCLC Unmet Needs
EGFR + NSCLC Companies
Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux Therapeutics, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Genor Biopharma, J Ints Bio, Avistone Pharmaceuticals, Mythic Therapeutics and others.
EGFR Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
EGFR + NSCLC Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Discover the latest advancements in EGFR + NSCLC treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ EGFR + NSCLC Market Drivers and Barriers, and Future Perspectives
Scope of the EGFR + NSCLC Pipeline Report
Coverage- Global
EGFR + NSCLC Companies- Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux Therapeutics, Daiichi Sankyo Company, Suzhou Puhe Pharmaceutical Technology, Genor Biopharma, J Ints Bio, Avistone Pharmaceuticals, Mythic Therapeutics and others.
EGFR+NSCLC Pipeline Therapies- IN10018, Furmonertinib, Oral S-1 + Oral Osimertinib, YH25448, JS111 capsules (AP-L1898), Osimertinib, Gefitinib, RC108, Sunvozertinib, and others.
EGFR + NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
EGFR + NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of EGFR + NSCLC Pipeline on our website @ EGFR + NSCLC Emerging Drugs and Companies
Table of Contents
Introduction
Executive Summary
EGFR Non-Small Cell Lung Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
EGFR Non-Small Cell Lung Cancer – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
CLN-081: Cullinan Oncology
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Drug Name: Company Name
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
BPI-361175: Betta Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Companies
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Products
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Unmet Needs
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Market Drivers and Barriers
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)- Future Perspectives and Conclusion
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Analyst Views
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Focused Investors Llc Reduces Stake in Microsoft
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Focused Investors Llc, managed by Bruce Gordon Veaco, recently executed a significant transaction involving Microsoft ((MSFT)). The hedge fund reduced its position by 6,800 shares. Spark's Take on MSFT Stock According to Spark, TipRanks' AI Analyst, MSFT is a Outperform. Microsoft's overall stock score is driven by its strong financial performance and positive earnings call sentiment. The company benefits from consistent revenue growth and high profitability, supported by effective cash flow management and a solid balance sheet. Technical indicators show positive momentum, although overbought conditions suggest caution. The high P/E ratio reflects market confidence but also hints at potential overvaluation. Continued strength in cloud and AI services positions Microsoft well for future growth. To see Spark's full report on MSFT stock, click here. More about Microsoft YTD Price Performance: 20.48% Average Trading Volume: 19,965,959 Current Market Cap: $3759.9B Disclaimer & Disclosure Report an Issue
Globe and Mail
4 hours ago
- Globe and Mail
Chubb Ltd Reports Record Earnings and Strong Growth
Chubb Ltd ((CB)) has held its Q2 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Chubb Ltd's recent earnings call painted a picture of robust financial health, marked by record-breaking earnings per share (EPS), underwriting income, and international premium growth. Despite facing challenges such as competitive pressures in large account property markets and softening financial lines pricing, the overall sentiment was overwhelmingly positive, underscoring the company's strong performance. Record Operating EPS Chubb Ltd achieved a milestone with its core operating EPS reaching a record $6.14, reflecting a 14% increase from the previous year. This impressive growth underscores the company's effective strategies and operational efficiency. Strong Core Operating Income The company reported a record core operating income of $2.5 billion, marking a 13% increase year-over-year. This significant growth highlights Chubb's ability to generate substantial revenue from its core operations. Impressive Underwriting Income Underwriting income soared to $1.6 billion, up 15% from the prior year, resulting in a combined ratio of 85.6%. This improvement indicates a strong underwriting performance and effective risk management. Significant Tangible Book Value Growth Chubb Ltd's tangible book value per share grew by an impressive 23.7% from a year ago and 8% from the previous quarter, showcasing the company's strong financial foundation and shareholder value enhancement. Robust Premium Growth in Life Insurance The Life Insurance division saw premiums grow by nearly 17.5%, reflecting Chubb's successful expansion and market penetration in this sector. Continued Growth in International Markets Chubb's international markets demonstrated strong performance, with premiums in Asia growing over 12.5%, Europe over 8%, and Latin America over 17%. This growth highlights the company's effective global strategy and market diversification. Strong Cash Flow and Investment Income Operating cash flow was robust at $3.2 billion, and adjusted net investment income rose by 8% to nearly $1.7 billion. These figures underscore Chubb's strong cash generation capabilities and investment acumen. Competitive Large Account Property Market The large account-related short-tail business has become increasingly competitive, with softening prices posing challenges. However, Chubb remains focused on maintaining its market position. Property Pricing Pressure Property pricing experienced a decline of 2.5%, with rates down about 7%, offset by an exposure change of 4.9%. This trend reflects the competitive nature of the property market. Softness in Financial Lines Pricing Financial lines pricing faced softness, with a 1.2% decrease in North America and over 6.5% internationally. Chubb continues to navigate these challenges while seeking opportunities for growth. Catastrophe Losses Chubb reported pretax catastrophe losses of $630 million for the quarter, highlighting the impact of unforeseen events on the company's financials. Forward-Looking Guidance Looking ahead, Chubb Ltd remains optimistic about its growth prospects. The company anticipates continued strong financial performance, with a diversified global presence supporting its expansion. The global P&C premiums are expected to grow, with notable increases in consumer P&C and Life Insurance premiums. Despite a competitive U.S. commercial P&C market, Chubb is well-positioned for sustained growth. In conclusion, Chubb Ltd's earnings call reflects a strong positive sentiment, driven by record financial metrics and strategic growth in international markets. While challenges in pricing and competition exist, the company's robust performance and forward-looking strategies suggest a promising future.
Globe and Mail
4 hours ago
- Globe and Mail
Hive Digital Technologies: Scaling Up to Shape the Next Era of Bitcoin
A green-powered expansion plan aims to position Hive among the top players in global digital mining In a world where digital finance is becoming less of a concept and more of a cornerstone, Hive Digital Technologies is acting fast. The company is set to quadruple operations in 2025, with a clear goal: to secure 3% of the global bitcoin mining network. What sets Hive apart is its commitment to green energy, building a tech-forward infrastructure that's both scalable and environmentally conscious. With this expansion, Hive isn't just riding the crypto wave—it's laying down long-term roots in the evolving digital asset economy. For those watching the future of finance unfold, Hive's momentum reflects the growing intersection of blockchain, sustainability, and global scale. Published by BTV - The Agency
